Trulieve Rings the NYSE Bell, But the Hard Part Is Just Beginning

Trulieve completes NYSE listing, redomiciles to Delaware, gains DEA registrations, but Q2 net loss hits $406M on restructuring charges.

When Trulieve Cannabis Corp. executives stepped up to ring the closing bell at the New York Stock Exchange on Tuesday, the ceremony marked more than a photo opportunity. It was the public punctuation of a months-long corporate overhaul that has reshaped the company's legal identity, its regulatory standing and its balance sheet — often in ways that look messier on paper than they do in practice.

The company, which trades under the ticker TRLV, became the first US cannabis operator to list on the NYSE back on June 10. That milestone, however, was merely the starting point for a broader transformation that has since included a change of corporate domicile, a federal regulatory breakthrough and a restructuring charge large enough to wipe out an entire quarter's earnings.

A New Home in Delaware

The most consequential structural move came on August 11, when Trulieve officially relocated its legal headquarters from British Columbia to Delaware. Shareholders had approved the redomiciliation on August 5 with overwhelming support — 71.76 million votes in favor against just 383,078 opposed, a margin of roughly 99.5 percent — and the British Columbia Supreme Court issued its final order on August 10.

For CEO Kim Rivers, the shift represents a strategic inflection point. The move gives the company a more natural pathway to US investors and improves its prospects for inclusion in major indices, she said. It also severed the final tie to the company's Canadian exchange roots, a prerequisite for the NYSE listing that followed.

DEA Registration Adds a Regulatory Feather

Alongside the domicile change, Trulieve has been quietly checking off regulatory boxes. All 207 of its medical dispensaries are now registered with the US Drug Enforcement Administration, a development made possible by the federal government's April decision to reschedule medical marijuana into Schedule III.

Inspections have already been completed in Florida, Pennsylvania and West Virginia. The registration is more than a compliance formality — it opens the door to conventional distribution and pharmacy channels. Trulieve has already begun shipping to licensed independent pharmacies in Georgia, where it launched an expanded medical program with new product formats in July.

The Numbers Tell a Two-Sided Story

The operational picture, however, remains clouded by the costs of transformation. Trulieve generated $271 million in revenue during the second quarter of 2026, with retail accounting for 94 percent of that figure. Gross margin came in at a healthy 60 percent, and adjusted EBITDA reached $98 million. Free cash flow for the quarter was $32 million.

Yet the bottom line told a different tale. The company posted a GAAP net loss of $406 million, or $2.10 per share, driven by a non-cash charge of $403.3 million tied to the deconsolidation of its Harvest business — a restructuring step required for the NYSE listing. The secondary source puts that charge at $407 million, a minor discrepancy in rounding that does not change the underlying picture: this was an accounting cleanup, not an operational failure.

The market's initial reaction was nonetheless skittish. Shares fell 2.94 percent to $8.74 after the earnings release, with investors expressing unease about the lowered full-year cash flow guidance and the sheer complexity of the restructuring. The adjusted earnings per share of $0.11, which beat analyst estimates by 37.5 percent, did little to calm those nerves at the time.

A Buyback and a Rebound

Since that dip, sentiment has shifted. The stock closed at $10.25 on August 20, up 1.59 percent on the day, after trading in a range of $9.80 to $10.29 on volume of roughly 1.26 million shares. That puts the company's market capitalization at just under $2 billion, with a 52-week range of $4.62 to $13.28 — a recovery from the year's lows, though still well off the 2026 peak.

Management has also moved to signal confidence in the company's valuation. Trulieve announced a share repurchase program of up to $50 million, or 8,495,038 voting common shares.

For the third quarter, the company guided to revenue comparable to the second quarter's medical-only figure of $222 million, which grew 4 percent sequentially. Trulieve also raised its full-year 2026 operating cash flow guidance to at least $225 million, after reporting $109 million in operating cash flow and $74 million in free cash flow for the first half.

What Investors Are Watching

The company continues to expand its physical footprint — a new medical dispensary opened in Marco Island, Florida, in early August, bringing the network to its current 207 locations. Rivers also participated in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12.

Four factors remain central to the investment thesis: exchange access, dispensary productivity, expansion into new states and cash flow development. The next major checkpoint arrives on November 11, when Trulieve reports third-quarter results. Whether the stock's autumn trajectory holds will depend on how smoothly the company integrates its newly streamlined, medical-only operating model — and whether the structural wins of the past several months begin to show up in the earnings line rather than just the headlines.